Add to a list

Inactive Instrument

International Stem Cell Corp Stock OTC Bulletin Board

ISCO

US4603781026

Biotechnology & Medical Research

OTC Markets Traded

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

07-23	American Type Culture Collection Inc. entered into Membership Interest Purchase Agreement to acquire Lifeline Cell Technology, LLC from International Stem Cell Corporation for $25 million.	CI
05-14	International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Valuation: International Stem Cell Corp

Market Cap	2.4M 2.08M 1.94M 1.78M 3.35M 228M 3.4M 22.75M 8.93M 115M 9.01M 8.82M 379M	P/E 2024	-3.11x	P/E 2025	-2.68x
Enterprise Value	5.14M 4.45M 4.15M 3.81M 7.16M 489M 7.28M 48.72M 19.12M 245M 19.3M 18.88M 811M	EV / Sales 2024	0.36x	EV / Sales 2025	0.42x
Free-Float	29.26%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : International Stem Cell Corp

07-23	American Type Culture Collection Inc. entered into Membership Interest Purchase Agreement to acquire Lifeline Cell Technology, LLC from International Stem Cell Corporation for $25 million.	CI
05-14	International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-30	International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt	CI
11-13	International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-16	International Stem Cell Corporation Announces Extension of Loan Maturity with Detailed Terms on Principal and Interest	CI
25-08-14	International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-14	International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-28	International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-27	International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt	CI
24-11-13	International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-13	International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-14	International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

More news

Press Releases: International Stem Cell Corp

25-03-31	International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results	AQ
23-06-21	INTERNATIONAL STEM CELL CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
23-03-30	INTERNATIONAL STEM CELL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
23-03-16	INTERNATIONAL STEM CELL CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
22-11-14	INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

More press releases

Managers and Directors: International Stem Cell Corp

Manager	Title	Age	Since
Andrey Semechkin CEO	Chief Executive Officer	66	2009-10-31
Russell Kern CTO	Chief Tech/Sci/R&D Officer	40	2013-05-31

Director	Title	Age	Since
Russell Kern BRD	Director/Board Member	40	2008-09-30
Paul Maier BRD	Director/Board Member	78	2007-06-30
Andrey Semechkin CHM	Chairman	66	2008-11-30

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.99%	+1.78%	+4.07%	+16.73%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.98%	+592.14%	43.61B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+33.39%	+8.85%	39.29B
BEONE MEDICINES AG	+5.60%	+10.21%	+16.76%	+85.72%	39.6B
CELLTRION, INC.	+2.21%	+6.75%	+21.31%	+53.37%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+37.75%	+126.84%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+6.24%	+18.87%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+78.59%	+30.30%	12.77B
Average	+2.12%	+6.32%	+85.64%	+116.60%	29.39B
Weighted average by Cap.	+2.54%	+6.10%	+104.25%	+140.79%

See all sector performances

International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and types of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

	2024	2025
Net sales	9.08M 7.86M 7.34M 6.73M 12.66M 865M 12.86M 86.1M 33.79M 433M 34.12M 33.37M 1.43B	9.1M 7.87M 7.35M 6.74M 12.68M 866M 12.88M 86.24M 33.85M 434M 34.17M 33.42M 1.44B
Net income	-209K -181K -169K -155K -291K -19.89M -296K -1.98M -777K -9.97M -785K -768K -32.96M	-418K -362K -338K -310K -583K -39.78M -592K -3.96M -1.55M -19.94M -1.57M -1.54M -65.92M
Net Debt	2.61M 2.26M 2.11M 1.93M 3.64M 248M 3.7M 24.74M 9.71M 125M 9.8M 9.59M 412M	2.74M 2.37M 2.21M 2.03M 3.82M 261M 3.88M 25.97M 10.19M 131M 10.29M 10.06M 432M

International Stem Cell Corp Stock OTC Bulletin Board

Stocks

ISCO

US4603781026

Biotechnology & Medical Research

Valuation: International Stem Cell Corp

Latest news : International Stem Cell Corp

Press Releases: International Stem Cell Corp

Managers and Directors: International Stem Cell Corp

Other Biotechnology & Medical Research

Financials

Company Profile